myNEO Therapeutics aims this year to double the team in size due to our growing project portfolio with multiple different partners. The antigen discovery team has been joined by Gitta Boons and Lies van Olmen earlier this year and we are currently recruiting at least...
CureVac (Nasdaq: CVAC) and myNEO Therapeutics will partner to identify novel targets for mRNA-based cancer vaccine development. We’re convinced that combining our tumor characterization and antigen discovery methods with an mRNA vaccination technology holds great...
Abera Bioscience, a listed Swedish company with vaccine platforms for prophylactic and therapeutic vaccines today signed an agreement with Belgian company myNEO Therapeutics for collaboration within the antigen discovery field. The companies will work closely together...
Opgeven Is Geen Optie (OIGO) is organizing an info session on March 24th where Lien Lybaert will explain in understandable language to cancer patients, their loved ones & sympathizers what has fascinated her for 10 years now: IMMUNOTHERAPY. What is the role of the...
EIT Health Catapult provides investors and industry representatives an excellent opportunity to gain access to a concentrated elite group of top European start-up companies keen to collaborate with strong partners, when they take their first steps towards economic...
The biotech industry in Ghent is very much alive. This is also proven by myNEO Therapeutics a young company that develops antigen discovery technology for personalized cancer treatments. Through sequencing of the entire genome, a technique that has been around for...
